1. Home
  2. OBK vs AUPH Comparison

OBK vs AUPH Comparison

Compare OBK & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Bancorp Inc.

OBK

Origin Bancorp Inc.

HOLD

Current Price

$54.26

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$16.11

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OBK
AUPH
Founded
1912
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
2.1B
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
OBK
AUPH
Price
$54.26
$16.11
Analyst Decision
Strong Buy
Buy
Analyst Count
6
4
Target Price
$46.67
$17.25
AVG Volume (30 Days)
149.9K
921.0K
Earning Date
04-22-2026
05-07-2026
Dividend Yield
2.13%
N/A
EPS Growth
N/A
5075.00
EPS
1.97
0.53
Revenue
N/A
$283,055,000.00
Revenue This Year
$26.43
$17.54
Revenue Next Year
$5.79
$15.74
P/E Ratio
$27.22
$30.66
Revenue Growth
N/A
20.38
52 Week Low
$32.13
$10.34
52 Week High
$55.57
$19.25

Technical Indicators

Market Signals
Indicator
OBK
AUPH
Relative Strength Index (RSI) 54.39 50.24
Support Level $52.46 $15.55
Resistance Level $55.29 $16.40
Average True Range (ATR) 0.84 0.38
MACD 0.02 -0.04
Stochastic Oscillator 63.20 13.95

Price Performance

Historical Comparison
OBK
AUPH

About OBK Origin Bancorp Inc.

Origin Bancorp Inc is a financial holding company that provides personalized, relationship banking to businesses, municipalities, and personal clients in the communities it serves. The company offers a broad range of financial services and operates more than 56 locations in Dallas/Fort Worth, East Texas, Houston, North Louisiana, Mississippi, South Alabama, and the Florida Panhandle. It also provides insurance agency products and services through its wholly owned insurance agency subsidiary. The company operates in one business segment, community banking, and is mainly engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: